Allergy Therapeutics Plc has announced that finnCap Ltd, the advisor to offeror Skygem Acquisition Limited, has made a public dealing disclosure in relation to Allergy Therapeutics' securities. The disclosure states that finnCap Ltd has no interests or short positions in Allergy Therapeutics' securities. The disclosure also mentions that these transactions have taken place as a consequence of book flattening and that the Panel Executive has informed finnCap Ltd that such transactions are permitted and have no Code consequences.

The disclosure does not provide any information about the nature of the transactions or the reasons behind them. It only states that finnCap Ltd has sold 1 ordinary share of Allergy Therapeutics at a price of 2.76 pence per share.

No other positions or dealings are disclosed in the document. The disclosure also states that there are no indemnity or option arrangements, agreements, or understandings relating to Allergy Therapeutics' securities.

Overall, the disclosure provides limited information about the transactions and does not provide any insights into the intentions or motivations behind them.